May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Pattern of Uveitis Associated Macular Edema as a Factor Affecting Response to Intravitreal Bevacizumab
Author Affiliations & Notes
  • S. Pujari
    Ophthalmology, Mersi, Cambridge, Massachusetts
  • K. Quinones
    Ophthalmology, Mersi, Cambridge, Massachusetts
  • C. S. Foster
    Ophthalmology, Mersi, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  S. Pujari, None; K. Quinones, None; C.S. Foster, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4731. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Pujari, K. Quinones, C. S. Foster; Pattern of Uveitis Associated Macular Edema as a Factor Affecting Response to Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4731. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the response to bevacizumab in different patterns of uveitic macular edema.

Methods: : 34 eyes with uveitic macular edema receiving single (25 eyes) or two doses of bevacizumab intravitreal injections (2.5mg) were prospectively followed for 6 months. Anatomical outcomes were assessed by OCT.

Results: : Three patterns of macular edema were identified and percentages of eyes showing response (defined as 25% reduction in central foveal thickness) are as follows:diffuse thickening, 29%(4/14) , cystoid edema,56%(9/16), serous detachment without posterior hyaloid traction,50%(2/4). Four eyes each having diffuse thickening and cystoid edema and one eye having serous detachment without posterior hyaloid traction received second doze of intravitreal bevacizumab.

Keywords: macula/fovea • edema • autoimmune disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×